Sudhakar Veeranki

Dr. Sudhakar Veeranki


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
SVSudhakar Veeranki
Sudhakar Veeranki
SGSrikanth Givvimani
Srikanth Givvimani
SKSourav Kundu
Sourav Kundu
NMNaira Metreveli
Naira Metreveli
SPSathnur Pushpakumar
Sathnur Pushpakumar
STSuresh C. Tyagi
Suresh C. Tyagi

Verified
Journal Article
Open access
PDF file
SVSudhakar Veeranki
Sudhakar Veeranki
STSuresh Tyagi
Suresh Tyagi
Hyperhomocysteinemia (HHcy) is a systemic medical condition and has been attributed to multi-organ pathologies. Genetic, nutritional, hormonal, age and gender differences are involved in abnormal homocysteine (Hcy) metabolism that produces HHcy. Homocysteine is an intermediate for many key processes such as cellular methylation and cellular antioxidant potential and imbalances in Hcy production and/or catabolism impacts gene expression and cell signaling including GPCR signaling. Furthermore, HHcy might damage the vagus nerve and superior cervical ganglion and affects various GPCR functions; therefore it can impair both the parasympathetic and sympathetic regulation in the blood vessels of skeletal muscle and affect long-term muscle function. Understanding cellular targets of Hcy during HHcy in different contexts and its role either as a primary risk factor or as an aggravator of certain disease conditions would provide better interventions. In this review we have provided recent Hcy mediated mechanistic insights into different diseases and presented potential implications in the context of reduced muscle function and integrity. Overall, the impact of HHcy in various skeletal muscle malfunctions is underappreciated; future studies in this area will provide deeper insights and improve our understanding of the association between HHcy and diminished physical function.

1 May 2015 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SVSudhakar Veeranki
Sudhakar Veeranki
LWLee J. Winchester
Lee J. Winchester
STSuresh C. Tyagi
Suresh C. Tyagi

1 January 2016 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ICIlya Chernyavskiy
Ilya Chernyavskiy
SVSudhakar Veeranki
Sudhakar Veeranki
USUtpal Sen
Utpal Sen
STSuresh C. Tyagi
Suresh C. Tyagi

1 April 2015 in Nitric Oxide
Verified
Journal Article
Closed access
SVSudhakar Veeranki
Sudhakar Veeranki
STSuresh C. Tyagi
Suresh C. Tyagi

1 March 2017 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
SVSudhakar Veeranki
Sudhakar Veeranki
SGSiva K. Gandhapudi
Siva K. Gandhapudi
STSuresh C. Tyagi
Suresh C. Tyagi
Although hyperhomocysteinemia (HHcy) is an independent risk factor for cardiovascular diseases (CVD), there is a debate on whether HHcy is a risk factor or just a biomarker. Interestingly, homocysteine lowering strategies in humans had very little effect on reducing the cardiovascular risk, as compared with animals; this may suggest heterogeneity in human population and epigenetic alterations. Moreover, there are only few studies that suggest the idea that HHcy contributes to CVD in the presence of other risk factors such as inflammation, a known risk factor for CVD. Elevated levels of homocysteine have been shown to contribute to inflammation. Here, we highlight possible relationships between homocysteine, T cell immunity, and hypertension, and summarize the evidence that suggested these factors act together in increasing the risk for CVD. In light of this new evidence, we further propose that there is a need for evaluation of the causes of HHcy, defective remethylation or defective transsulfuration, which may differentially modulate hypertension progression, not just the homocysteine levels.